Novo Nordisk expects phase III data for diabetes app imminently

Results from a phase III trial in which Doseguide, an app solution developed by the Danish drugmaker, featured prominently are expected within a few weeks.

Photo: Tidsvilde Stine/Ritzau Scanpix

In just a few weeks, Novo Nordisk will receive data from a phase III study in which the pharmaceutical company’s own app, Doseguide, played an important role, Executive Vice President for Development at Novo Nordisk Martin Holst Lange tells MedWatch.

The Doseguide app is meant to give patients dose recommendations based on their blood sugar and previous doses.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs